Literature DB >> 31158726

Effect of Surgery-Specific Opioid-Prescribing Education in a Safety-Net Hospital.

Brian K Yorkgitis1, Cole Paffett2, Gabriel A Brat3, Marie Crandall2.   

Abstract

BACKGROUND: As the nation works to improve the opioid epidemic, safer opioid prescribing is needed. Prescriber education is one method to assist with this aim. To gauge current surgical residents' opioid prescribing practices at a safety-net hospital, an evaluation was completed before a general surgery-specific opioid prescribing education (OPE) session. The effectiveness of this OPE was measured through a postparticipation evaluation.
METHODS: A voluntary, anonymous evaluation immediately before and after a one-hour OPE session was performed at an urban safety-net hospital. Descriptive statistics and Student's t-test comparisons of means were performed to analyze the results.
RESULTS: Twenty-three residents completed the surveys. Eleven (47.8%) completed prior OPE with the most common modality being online (7, 63.6%). No participant performed an opioid risk assessment before prescribing opioids. More than half of the residents (14, 60.9%) never used the prescription drug monitoring program. Less than 1/3 (7, 30.4%) used preoperative gabinoids (gabapentin or pregabalin) for elective surgeries. Only two residents provided information on unused opioid disposal. After the OPE, the participants were more likely to prescribe preoperative gabinoids (7 versus 21, P < 0.001). The mean opioid pills prescribed for laparoscopic cholecystectomy, open inguinal hernia repair, laparoscopic ventral hernia repair, and laparoscopic appendectomy were reduced by 2.6 (14.2%, P = 0.23), 3.7 (18.9%, P = 0.07), 2.6 (13.1%, P = 0.23), and 1.1 (7.3%, P = 0.60) pills, respectively.
CONCLUSION: A short OPE delivered to surgical residents at a safety-net hospital significantly improved the use of preoperative gabinoids. Although the pill count reductions after the OPE were not statistically significant, there was a consistent reduction in amount of opiates prescribed after the OPE. However, clinical significance is important, as a reduction in any amount of opioid medication can help deter misuse and diversion. This suggests resident surgeons could participate in a specialty-specific OPE to improve opioid prescribing.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multimodal-pain control; Opioid education; Opioid prescribing; Resident education; Surgery

Year:  2019        PMID: 31158726     DOI: 10.1016/j.jss.2019.05.003

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Surgical Residency Programs Should Leverage Recent Advances in National Policy, Real-World Data, and Public Opinion to Improve Post-Surgery Opioid Prescribing.

Authors:  Jayson S Marwaha; Chris J Kennedy; Gabriel A Brat
Journal:  J Grad Med Educ       Date:  2022-02

2.  Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019).

Authors:  Chris Delcher; Nathan Pauly; Patience Moyo
Journal:  Curr Opin Psychiatry       Date:  2020-07       Impact factor: 4.787

3.  Study protocol: randomized controlled trial of opioid-free vs. traditional perioperative analgesia in elective orthopedic surgery.

Authors:  Elaine Z Shing; Daniel Leas; Caleb Michalek; Meghan K Wally; Nady Hamid
Journal:  BMC Musculoskelet Disord       Date:  2021-01-23       Impact factor: 2.362

4.  Does An ERAS Protocol Reduce Postoperative Opiate Prescribing in Plastic Surgery?

Authors:  Heather R Faulkner; Suzanne B Coopey; Rachel Sisodia; Bridget N Kelly; Lydia R Maurer; Dan Ellis
Journal:  JPRAS Open       Date:  2021-10-26

5.  Day-of-Surgery Gabapentinoids and Prolonged Opioid Use: A Retrospective Cohort Study of Medicare Patients Using Electronic Health Records.

Authors:  Jessica C Young; Nabarun Dasgupta; Brooke A Chidgey; Til Stürmer; Virginia Pate; Michael Hudgens; Michele Jonsson Funk
Journal:  Anesth Analg       Date:  2021-11-01       Impact factor: 6.627

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.